Phase II study of gemcitabine in patients with advanced pancreatic cancer

British Journal of Cancer

Volumn 73, Issue 1, 1996, Pages 101-105

  Carmichael, J ^a,b,f   Fink, U ^c   Russell, R C G ^d   Spittle, M F ^d   Harris, A L ^a   Spiessi, G ^c   Blatter, J ^d,e  

^a CHURCHILL HOSPITAL   (United Kingdom)

^b Academic Unit of Oncology   (United Kingdom)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d MIDDLESEX HOSPITAL   (United Kingdom)

^e LILLY DEUTSCHLAND GMBH   (Germany)

^f NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

Advanced pancreatic cancer; Gemcitabine; Phase II clinical trial; Solid tumour; Tumour marker

Indexed keywords

ANALGESIC AGENT; CA 19-9 ANTIGEN; CA 195 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; GEMCITABINE; TUMOR MARKER;

ADULT; AGED; ANALGESIA; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DIAGNOSIS; DRUG EFFICACY; DRUG SAFETY; DRUG USE; EDEMA; FEMALE; HUMAN; INFLUENZA; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LIVER TOXICITY; MALE; METASTASIS; MULTICENTER STUDY; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PAIN; PAIN ASSESSMENT; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TUMOR VOLUME; VOMITING;

EID: 0030049697     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.18     Document Type: Article

References (18)

1. ABRATT RP, BEZWODA WR, FALKSON G, GOEDHALS L AND HACKING D. (1994). Efficacy and safety profile of gemcitabine in non-small cell lung cancer: a phase II study. J. Clin. Oncol., 12, 1535-1540.
2. ABBRUZZESE JL, GRUNEWALD R, WEEKS EA, GROVEL D, ADAMS T, NOWAK B, MINEISHI S, TARASOFF P, SALTERLEE W, RABER MN AND PLUNKETT W. (1991). A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J. Clin. Oncol., 9, 491-498.
3. ANDERSON H, LUND B, BACH F, THATCHER N, WALLING J AND HANSEN HH. (1994). Single agent activity of weekly gemcitabine in advanced non-small cell lung cancer: A phase II study. J. Clin. Oncol., 12, 1821-1826.
4. BRENNAN MF, KINSELLA TJ AND CASPER ES. (1993). Cancer of the pancreas. In Cancer: Principles & Practice of Oncology, Vol 3, 4th edn. De Vita VT Jr, Hellman S, Rosenberg SA. pp. 849-882. JB Lippincott: Philadelphia.
5. CARMICHAEL J, POSSINGER K, PHILIP P, BEYLARCH M, KERR H, WALLING J AND HARRIS AL. (1993). Difluorodeoxycytidine (gemcitabine): a phase II study in patients with advanced breast cancer (abstract 57). Proc. Am. Soc. Clin. Oncol., 12, 64.
6. CASPER ES, GREEN MR, KELSEN DP, HEELAN RT, BROWN TD AND FLAMBAUM CD. (1994). Phase II trial of gemcitabine (2′,2′difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest. New Drugs, 12, 29-34.
7. CORMIER Y, EISENHAUER E, MULDAL A, GREGG R, AYOUB J, GOSS G, STEWART D, TARASSOFF P AND WONG D. (1994). Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer. A study of the National Cancer Institute of Canada Clinical Treatment Group. Ann. Oncol., 5, 283-285.
8. HEINEMANN V, HERTEL L, GRINDEY GB AND PLUNKETT W. (1988). Cellular elimination of 2′,2′-difluorodeoxycytidine 5′-triphosphate (dFdCTP). Proc. Am. Assoc. Cancer Res., 29, 504.
9. HERTEL LW, BODER GB, KROIN JS, RINZEL SM, POORE GA, TODD GC AND GRINDEY GB. (1990). Evaluation of the antitumour activity of gemcitabine, (difluoro-2′-deoxycytidine). Cancer Res., 50, 4417-22.
10. HUANG P, CHUBB S, HERTEL L, GRINDEY GB AND PLUNKET W. (1991). Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res., 51, 6110-6117.
11. JENSEN OM, ESTÈVE J, MØLLER H AND RENARD H. (1990). Cancer in the European Community and its Member States. Eur. J. Cancer, 26, (11/12): 1167-1256.
12. LUND B, HANSEN OP, THEILADE K, HANSEN M AND NEIJT JP. (1994). Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) in previously treated ovarian cancer. J. Natl Cancer Inst., 86, 1530-1533.
13. MOORE M, ANDERSEN I, BURRIS H, TARASSOFF P, GREEN M, CASPER E, PORTENOY R, MODIANO M, CRIPPS C, NELSON R, STORNIOLO A AND VON HOFF D. (1995). A randomized trial of gemcitabine (GEM) versus 5FU as first-line therapy in advanced pancreatic cancer (abstract 473). Proc. Am. Soc. Clin. Oncol., 14, 199.
14. PLUNKETT W, GANDHI V, CHUBB S, NOWAK B, HEINEMANN V, MINEISHI S, SEN A, HERTEL LW AND GRINDEY GB. (1989). 2′,2′-Difluorodeoxycytidine metabolism and mechanism of action in human leukaemia cells. Nucleosides Nucleotides, 8, (5-6) 775-785.
15. ROTHENBERG ML, BURRIS HA, ANDERSEN JS, MOORE M, GREEN MR, PORTENOY RK, CASPER ES, TARASSOFF PG, STORNIOLO AM AND VON HOFF DD. (1995). Gemcitabine: effective palliative therapy for pancreas cancer patients failing 5-FU (abstract 470). Proc. Am. Soc. Clin. Oncol., 14, 198.
16. SHEPHERD FA, GATZEMEIER U, GOTFRIED M, WEYNANTS P, COTTIER B, GROEN H, ROSSO R, MATTSON K, CORNES-FUNES H, TONATO M, HATTY S AND VOI M. (1993). An extended phase II study of gemcitabine in non-small cell lung cancer (abstract 1096). Proc. Am. Soc. Clin. Oncol., 12 (suppl), 330.
17. XU Z-Y AND PLUNKETT W. (1992). Modulation of deoxycytidine deaminase in intact human leukemia cells. Action of 2′,2′-difluorodeoxycytidine. Biochem. Pharmacol., 44 (9), 1819-1827.
18. WORLD HEALTH ORGANIZATION. (1979). WHO Handbook for Reporting Results of Cancer Treatment. p 48. WHO: Geneva.